iCONM Investor Day Japan Fall 2026

iCONM in collaboration with BioLabs, together with Astellas Pharma, LINK-J, and BioLabs Global, hosted Investor Day Japan Fall 2026 at the Nihonbashi Life Science Building in Tokyo. Building on the inaugural event held in March, this second edition featured eight selected biotech startups from Japan and abroad.
The event brought together global investors and life sciences professionals for candid discussions on translating scientific discoveries into commercial opportunities, navigating international markets, and securing investment. 150 participants joined the event, with around 100 of those in person.
Pitch Session
The pitch session opened with remarks from the BioLabs team, joining virtually from Boston. Eight startups selected through a competitive screening process each delivered a five-minute pitch, followed by a five-minute live Q&A with six seasoned investors and venture builders.
The judges challenged founders with questions on scientific differentiation, clinical development strategies, competitive positioning, and fundraising plans. These exchanges offered the presenting startups valuable perspectives to inform their next steps, while giving both in-person and virtual attendees a firsthand look at the considerations that shape real-world investment decisions.
Each startup was evaluated across five criteria: scientific innovation, clinical development potential, business strategy, investment attractiveness, and pitch delivery. Each category was scored on a five-point scale, for a maximum total of 25 points.
The Eight Competitors

Materia Therapeutics | United States / Japan
Developing MATH-01, a tumor-activated platinum-based chemotherapy designed to selectively target pancreatic cancer.
LoopLab Bio | Austria
Developing a novel therapeutic approach to induce allergen-specific immune tolerance through its proprietary Fc-engager technology.
Apotek Biotechnologies | Taiwan / United States
Combining AI-driven discovery with experimental validation to identify and develop drug candidates in oncology and immunology.
University of Shizuoka | Japan
Developing MF1, an FABP3 inhibitor designed to reduce abnormal alpha-synuclein accumulation and neuronal damage in Parkinson’s disease and dementia with Lewy bodies.
Curogen | South Korea / United States
Developing novel oral small-molecule therapeutics for autoimmune and inflammatory conditions, including inflammatory bowel disease and hidradenitis suppurativa.
HiLung | Japan
Developing HL001, an inhaled LPA1 receptor antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).
Surzen Biotherapeutics | Japan
Developing peptide therapeutics designed to prolong opioid analgesia and reduce the need for additional dosing.
Crafton Biotechnology | Japan
Advancing a proprietary mRNA platform that enables the body to produce therapeutic antibodies in vivo.
The Six Judges

- Andrew Levin | Investor, Entrepreneur
- Anja König | Global Head, Novartis Venture Fund (NVF)
- Jeff Goater | Partner, The Column Group (TCG)
- Kelly Qiao | Senior Principal, B Capital
- Ken Horne | Managing Partner, AN Venture Partners (ANV)
- Nandita Shangari | Managing Director, RA Capital
Panel Discussion: What Makes a Biotech Globally Investable?
The 45-minute panel discussion brought together investors from the judging panel to explore what makes a biotech startup an attractive investment on the global stage. Drawing on their firsthand investment experience, the panelists examined what distinguishes compelling science from an investable business, the factors that lead investors to pass on an opportunity, and the strategies Japanese biotech companies can pursue to compete internationally. The conversation also explored the opportunities and challenges within Japan’s biotech ecosystem, including the commercialization of academic discoveries, pharmaceutical spinouts, and engagement with international investors.

Beyond scientific promise, the discussion offered a closer look at how investors assess the broader fundamentals of a biotech business, from leadership and clinical development strategies to financing, execution, and global expansion.
Congratulations to HiLung!

Congratulations to the HiLung team on this well-deserved recognition! We also extend our sincere appreciation to all eight presenting startups for sharing their innovative science and ambitious visions for the future.
Conversations Beyond the Stage

Beyond the pitches and panel discussion, the event brought together a diverse mix of biotech startups, venture capital firms, pharmaceutical companies, academic researchers, and startup ecosystem organizations from Japan and abroad, drawing on the complementary networks of all four co-hosts. Conversations extended beyond investor-founder interactions, with startups exchanging perspectives on development strategies and shared business challenges. These discussions created opportunities to forge new relationships and explore potential research collaborations and strategic partnerships.
Brought to us by iCONM—the original can be found on their site here.
